Quintiles helepd develop or commercialize 73 percent of the best selling vaccine products around the world in 2011, and it kept up the pace in 2012 in the judgment of the vaccine industry.
The world’s largest life science services firm was named the top clinical research organization by the Vaccine Industry Excellence Awards for the second consecutive year at the World Vaccine Congress in Washington, D.C.
Awards are given to firms and individuals for contributions to the industry over the past year.
“We’re proud to be recognized by our customers and peers as the Best CRO,” said Dr. Christopher Cabell, senior vice president, Therapeutic Delivery Unit. “We work every day to advance the development of quality vaccines and anti-infective products. This achievement celebrates our commitment to create a healthier world.”
The CRO award is based on votes by customers to determine five finalists, which are then reviewed by a panel of judges based on these criteria:
- Range of services provided in niche and core therapeutic areas;
- Methods of performance improvement or introduction of new services;
- Attention to and quality of relationships with clients;
- Reaching of milestones and final/ongoing outcomes; and
- Building and maintaining existing and long-term partnerships.
Quintiles, which is in the process of a public stock offering estimated at $600 million, has also helped develop or commercialize the top 50 best-selling drugs on the market.
[QUINTILES ARCHIVE: Check out more than a decade of Quintiles stories as reported in WRAL Tech Wire.]
